Pulmonary Fibrosis Foundation to host annual fundraiser Oct. 13
The Pulmonary Fibrosis Foundation (PFF) is hosting its annual dinner, Breathe Benefit 2012: Community Inspiring a Cure, at the legendary Drake Hotel on Oct. 13 at 6:30 p.m.
For the second year, the event will be emceed by Mary Ann Ahern from NBC5 News.
The benefit will be attended by medical and research professionals, patients, caregivers, family members, and other valued supporters of the PFF. The evening will include cocktails, dinner, entertainment, a silent auction, and an awards ceremony. Please join the PFF for this inspirational event.
Learn more about the Breathe Benefit 2012 dinner and purchase tickets at http://www.pulmonaryfibrosis.org/breathebenefit2012.
About the Pulmonary Fibrosis Foundation:
The Mission of the Pulmonary Fibrosis Foundation (PFF) is to help find a cure for idiopathic pulmonary fibrosis (IPF), advocate for the pulmonary fibrosis community, promote disease awareness, and provide a compassionate environment for patients and their families. The PFF collaborates with physicians, organizations, patients and caregivers worldwide. On December 5-7 2013, the PFF will host its second biennial international scientific conference, Pulmonary Fibrosis Summit 2013. For more information visit www.pulmonaryfibrosis.org or call 888-773-6741.
About Idiopathic Pulmonary Fibrosis:
According to the National Institutes of Health, idiopathic pulmonary fibrosis (IPF) is a condition in which over a period of time the lung tissue becomes thickened, stiff, and scarred. The development of the scar tissue is called fibrosis. As the lung tissue becomes scarred and thicker, the lungs lose their ability to transfer oxygen into the bloodstream. As a result, the brain and the other organs don't receive the oxygen they need. In some cases, doctors can determine the cause of the fibrosis, but in most cases, there is not a known cause. When there is no known etiology for the fibrosis (and certain pathologic criteria are met) the disease id called idiopathic pulmonary fibrosis, or IPF. IPF affects approximately 200,000 individuals in the US, and the annual mortality is estimated to be 40,000. At present there are no FDA-approved medical therapies.